Imagion to Present Prostate Cancer Research Data at WMIC 2022

Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity……


Half-Year Results for the First Half of 2022 and Appendix 4D

Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast…


30 June 2022 4C screen shot

Quarterly Activity Report and Appendix 4C for 30 June 2022

Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2022. The announcement highlights: MagSense® HER2 imaging…


Iron Oxide Nanoparticles in Lipid Delivery System May Lead to Better Cancer Treatment

Lipids are frequently used to form drug carrying nanoparticles because of their favorable biocompatibility. However, construction of such drug-carrying lipid…


Q&A Session at 2022 Annual General Meeting

Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems' board of directors answer questions from…


Results of 2022 Annual General Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual…


Presentation Visuals from 25th May 2022 Annual General Meeting

The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here.    …


Chairman’s Address to Shareholders at 2022 Annual General Meeting

Imagion Biosystems recording and transcript of the Chairman’s address to shareholders at the 2022 Annual General Meeting. Dear Shareholders, It is my…


Health Industry Hub Interview

Bob Proulx sat down with Rozalina Sarkezians, Managing Director & Founder of Health Industry Hub, for a chat about Imagion Biosystem’s work developing our…


Quarterly Activity Report and Appendix 4C for 31 Mar 2022

Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022. The announcement highlights: MagSense® HER2 breast…